Pediatrix Medical Group, Inc. (MD) Stock Price & Analysis
Pediatrix Medical Group, Inc. (MD) rose 5.30% to USD 23.66 as of June 10, 2026 at 02:38 UTC, according to Nexqual real-time market data.
MD last closed at USD 22.47; the session ranged USD 22.54–23.71 on volume of 551,320 shares. Market capitalization is $1.94B, with a 52-week range of USD 11.84–24.99 (NYQ). Source: Nexqual, June 10, 2026 at 02:38 UTC.
Key Statistics (as of June 10, 2026 at 02:38 UTC)
| Price | USD 23.66 |
|---|---|
| Change | ▲ 5.30% (up) |
| Previous Close | USD 22.47 |
| Open | USD 22.66 |
| Day Range | USD 22.54 – 23.71 |
| 52-Week Range | USD 11.84 – 24.99 |
| Volume | 551,320 shares |
| Market Cap | $1.94B |
| Exchange | NYQ |
Technical Analysis (MD)
Nexqual's technical model rates MD "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:38 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.85 (neutral) |
| vs SMA50 | Above (USD 22.29) |
| MACD | 0.08 (positive) |
Analyst Ratings (MD)
Wall Street analysts rate MD "None" based on 6 analysts, with a mean price target of USD 23.17 (range USD 19–27), per Nexqual as of June 10, 2026 at 02:38 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 23.17 |
| High Target | USD 27 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 2 / 5 / 0 |
Earnings (MD)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.59 |
| Revenue Estimate | $478.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.44 vs est 0.38 ▲ beat |
| 2025-12-31 | USD 0.5 vs est 0.54 ▼ miss |
| 2025-09-30 | USD 0.67 vs est 0.47 ▲ beat |
| 2025-06-30 | USD 0.53 vs est 0.42 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:38 UTC.
Financials & Fundamentals (MD)
| Total Revenue | $1.93B |
|---|---|
| Revenue Growth (YoY) | +3.90% |
| Gross Margin | +26.09% |
| Operating Margin | +9.78% |
| Profit Margin | +9.02% |
| ROE | +20.89% |
| Debt / Equity | 71.68 |
| Current Ratio | 1.33 |
| Total Cash | $328.97M |
| Total Debt | $629.72M |
| Free Cash Flow | $163.73M |
Source: Nexqual, June 10, 2026 at 02:38 UTC.
Financial Health Score (MD)
Nexqual rates Pediatrix Medical Group, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:38 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 26%, operating 10% |
| Balance Sheet | Solid — $329M cash vs $630M debt |
| Cash Flow | Solid — FCF $164M, 9% margin |
| Efficiency | Strong — ROE 21%, ROA 7.3% |
Ownership (MD)
| Insider Ownership | +2.03% |
|---|---|
| Institutional Ownership | +105.50% |
| Shares Outstanding | 82.12M |
| Float | 78.87M |
| Short % of Float | +5.81% |
Source: Nexqual, June 10, 2026 at 02:38 UTC.
Leadership (MD)
Pediatrix Medical Group, Inc. is led by Mark S. Ordan (age 66), CEO & Executive Chairman, per Nexqual as of June 10, 2026 at 02:38 UTC.
| CEO & Executive Chairman | Mark S. Ordan (age 66) |
|---|---|
| Executive VP, Treasurer & CFO | Kasandra H. Rossi (age 52) |
| Executive VP & Chief Operating and Strategy Officer | D. Gregory Neeb (age 57) |
| Senior Vice President of People Services | Debra McRoberts |
| President of West Division | Kevin Pitzer |
Major Backers & Investors (MD)
Notable institutional backers of Pediatrix Medical Group, Inc. include American Century Companies Inc, Victory Capital Management Inc., Victory Portfolios-Victory Sycamore Small Company Opportunity Fund, according to Nexqual as of June 10, 2026 at 02:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 7.74% |
| Victory Capital Management Inc. | 4.68% |
| Victory Portfolios-Victory Sycamore Small Company Opportunity Fund | 3.2% |
| FMR, LLC | 2.76% |
| Wasatch Advisors LP | 2.5% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 25.24% |
| Vanguard Group | 18.95% |
| Dimensional Fund Advisors | 4.7% |
| State Street | 4.11% |
| Geode Capital | 2.66% |
Source: Nexqual, June 10, 2026 at 02:38 UTC.
From Pediatrix Medical Group, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed significant administrative expertise relating to our practice physician services.
- Analysis of the data within our clinical data warehouses across our neonatology and other pediatric subspecialty services allows us to provide feedback to our physicians and hospital partners and to develop and implement best practices, all with the goal of improving outcomes, creating efficiencies and ensuring patient satisfaction.
- This broad perspective allows us to better anticipate future needs and opportunities. • Quality and Safety.
- We believe that these initiatives have been enhanced by our integrated national presence together with our clinical and management information systems, which are an integral component of our clinical research and education activities.
Partnerships
- We believe telehealth reduces overall healthcare spending, improves access to quality care and facilitates collaboration with specialists while improving patient engagement and satisfaction. • Acquire Physician Practice Groups.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SEM | Select Medical Holdings Corpora | USD 16.63 | ▲ 0.54% |
| ACHC | Acadia Healthcare Company, Inc. | USD 25.5 | ▲ 4.17% |
| USPH | U.S. Physical Therapy, Inc. | USD 61.8 | ▼ 2.6% |
| UHS | Universal Health Services, Inc. | USD 146.59 | ▲ 0.98% |
| PBH | Prestige Consumer Healthcare In | USD 48.66 | ▲ 3.14% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:38 UTC. This page is informational and not investment advice.